Immunate Baxter may be available in the countries listed below.
Coagulation Factor VIII, Human is reported as an ingredient of Immunate Baxter in the following countries:
International Drug Name Search
Mircol may be available in the countries listed below.
Mequitazine is reported as an ingredient of Mircol in the following countries:
International Drug Name Search
Amlodipina Merck may be available in the countries listed below.
Amlodipine maleate (a derivative of Amlodipine) is reported as an ingredient of Amlodipina Merck in the following countries:
International Drug Name Search
Bisco-Magaldrat may be available in the countries listed below.
Magaldrate is reported as an ingredient of Bisco-Magaldrat in the following countries:
International Drug Name Search
Gerolin may be available in the countries listed below.
Citicoline sodium salt (a derivative of Citicoline) is reported as an ingredient of Gerolin in the following countries:
International Drug Name Search
Cortate may be available in the countries listed below.
Cortisone 21-acetate (a derivative of Cortisone) is reported as an ingredient of Cortate in the following countries:
International Drug Name Search
Compralgyl may be available in the countries listed below.
Codeine phosphate hemihydrate (a derivative of Codeine) is reported as an ingredient of Compralgyl in the following countries:
Paracetamol is reported as an ingredient of Compralgyl in the following countries:
International Drug Name Search
Kendural may be available in the countries listed below.
Ascorbic Acid sodium salt (a derivative of Ascorbic Acid) is reported as an ingredient of Kendural in the following countries:
Ferrous Sulfate is reported as an ingredient of Kendural in the following countries:
International Drug Name Search
Potassio Fosfato Fresenius may be available in the countries listed below.
Potassium Phosphate, Dibasic is reported as an ingredient of Potassio Fosfato Fresenius in the following countries:
Potassium Phosphate, Monobasic is reported as an ingredient of Potassio Fosfato Fresenius in the following countries:
International Drug Name Search
Mirobect may be available in the countries listed below.
Atenolol is reported as an ingredient of Mirobect in the following countries:
International Drug Name Search
Pramoxine Hydrochloride may be available in the countries listed below.
Pramoxine Hydrochloride (USAN) is also known as Pramocaine (Rec.INN)
International Drug Name Search
Glossary
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
Merck-Alprazolam may be available in the countries listed below.
Alprazolam is reported as an ingredient of Merck-Alprazolam in the following countries:
International Drug Name Search
Felodipine PCH may be available in the countries listed below.
Felodipine is reported as an ingredient of Felodipine PCH in the following countries:
International Drug Name Search
Terlomexin may be available in the countries listed below.
Fenticonazole nitrate (a derivative of Fenticonazole) is reported as an ingredient of Terlomexin in the following countries:
International Drug Name Search
BicaNorm may be available in the countries listed below.
Sodium Bicarbonate is reported as an ingredient of BicaNorm in the following countries:
International Drug Name Search
Fosinopril Arrowblue may be available in the countries listed below.
Fosinopril is reported as an ingredient of Fosinopril Arrowblue in the following countries:
International Drug Name Search
Acylcoffin may be available in the countries listed below.
Acetylsalicylic Acid is reported as an ingredient of Acylcoffin in the following countries:
Caffeine is reported as an ingredient of Acylcoffin in the following countries:
International Drug Name Search
Procarbazine Hydrochloride may be available in the countries listed below.
Procarbazine Hydrochloride (JAN, USAN) is known as Procarbazine in the US.
International Drug Name Search
Glossary
| JAN | Japanese Accepted Name |
| USAN | United States Adopted Name |
Alergipan may be available in the countries listed below.
Loratadine is reported as an ingredient of Alergipan in the following countries:
International Drug Name Search
Phylopen may be available in the countries listed below.
Flucloxacillin sodium salt (a derivative of Flucloxacillin) is reported as an ingredient of Phylopen in the following countries:
International Drug Name Search
Rebif 8.8 micrograms solution for injection in pre-filled pen
Rebif 22 micrograms solution for injection in pre-filled pen
Rebif 22 micrograms solution for injection in pre-filled pen
Rebif 44 micrograms solution for injection in pre-filled pen
Rebif 8.8 mcg and Rebif 22 mcg:
Each pre-filled pen contains 8.8 micrograms (2.4 MIU*) of interferon beta-1a** in 0.2ml solution.
Excipient: 1.0 mg benzyl alcohol
Each pre-filled pen contains 22 micrograms (6 MIU*) of interferon beta-1a** in 0.5ml solution.
Excipient: 2.5 mg benzyl alcohol
Rebif 22 mcg:
Each pre-filled pen contains 22 micrograms (6 MIU*) of interferon beta-1a** in 0.5ml solution.
Excipient: 2.5 mg benzyl alcohol
Rebif 44 mcg:
Each pre-filled pen contains 44 micrograms (12 MIU*) of interferon beta-1a** in 0.5ml solution.
Excipient: 2.5 mg benzyl alcohol
For a full list of excipients, see section 6.1.
* Million International Units, measured by cytopathic effect (CPE) bioassay against the in-house IFN beta-1a standard which is calibrated against the current international NIH standard (GB-23-902-531).
** produced in Chinese hamster ovary Cells (CHO-K1) by recombinant DNA technology.
Solution for injection in pre-filled pen.
Clear to opalescent solution, with pH 3.5 to 4.5 and osmolarity 250 to 450 mOsm/l.
Rebif is indicated for the treatment of relapsing multiple sclerosis.
In clinical trials, this was characterised by two or more acute exacerbations in the previous two years (see section 5.1).
Efficacy has not been demonstrated in patients with secondary progressive multiple sclerosis without ongoing relapse activity (see section 5.1).
Treatment should be initiated under supervision of a physician experienced in the treatment of the disease.
Rebif is available in three strengths: 8.8 micrograms, 22 micrograms and 44 micrograms. For patients initiating treatment with Rebif, Rebif 8.8 micrograms and Rebif 22 micrograms are available in a package that corresponds to the patient needs for the first month of therapy.
Posology
The recommended posology of Rebif is 44 micrograms given three times per week by subcutaneous injection.
The Rebif initiation package corresponds to the patient needs for the first month of treatment. When first starting treatment with Rebif, in order to allow tachyphylaxis to develop thus reducing adverse reactions, it is recommended that 8.8 micrograms be administered by subcutaneous injection three times per week during the initial 2 weeks of therapy. Thereafter, 22 micrograms be administered by subcutaneous injection three times per week in weeks 3 and 4, and the total of the 44 micrograms strength be administered from the fifth week onwards. A lower dose of 22 micrograms, also given three times per week by subcutaneous injection, is recommended for patients who cannot tolerate the higher dose in view of the treating specialist.
Paediatric population
No formal clinical trials or pharmacokinetic studies have been conducted in children or adolescents. However, limited published data suggest that the safety profile in adolescents from 12 to 16 years of age receiving Rebif 22 micrograms subcutaneously three times per week is similar to that seen in adults. There is very limited information on the use of Rebif in children under 12 years of age and therefore Rebif should not be used in this population.
Method of administration
RebiDose is a ready for use pre-filled pen for subcutaneous use.
It is intended for single use and should only be used following adequate training of the patient and/or carer.
For administration of Rebif with RebiDose, the instructions provided in the package leaflet should be followed.
Prior to injection and for an additional 24 hours after each injection, an antipyretic analgesic is advised to decrease flu-like symptoms associated with Rebif administration.
At the present time, it is not known for how long patients should be treated. Safety and efficacy with Rebif have not been demonstrated beyond 4 years of treatment. It is recommended that patients should be evaluated at least every second year in the 4-year period after initiation of treatment with Rebif and a decision for longer term treatment should then be made on an individual basis by the treating physician.
• Initiation of treatment in pregnancy (see section 4.6).
• Hypersensitivity to natural or recombinant interferon-β, or to any excipients.
• Current severe depression and/or suicidal ideation (see sections 4.4 and 4.8).
Patients should be informed of the most frequent adverse reactions associated with interferon beta administration, including symptoms of the flu-like syndrome (see section 4.8). These symptoms tend to be most prominent at the initiation of therapy and decrease in frequency and severity with continued treatment.
Rebif should be administered with caution to patients with previous or current depressive disorders in particular to those with antecedents of suicidal ideation (see section 4.3). Depression and suicidal ideation are known to occur in increased frequency in the multiple sclerosis population and in association with interferon use. Patients treated with Rebif should be advised to immediately report any symptoms of depression and/or suicidal ideation to their prescribing physician. Patients exhibiting depression should be monitored closely during therapy with Rebif and treated appropriately. Cessation of therapy with Rebif should be considered (see sections 4.3 and 4.8).
Rebif should be administered with caution to patients with a history of seizures, to those receiving treatment with anti-epileptics, particularly if their epilepsy is not adequately controlled with anti-epileptics (see sections 4.5 and 4.8).
Patients with cardiac disease, such as angina, congestive heart failure or arrhythmia, should be closely monitored for worsening of their clinical condition during initiation of therapy with interferon beta-1a. Symptoms of the flu-like syndrome associated with interferon beta-1a therapy may prove stressful to patients with cardiac conditions.
Injection site necrosis (ISN) has been reported in patients using Rebif (see section 4.8). To minimise the risk of injection site necrosis patients should be advised to:
• use an aseptic injection technique,
• rotate the injection sites with each dose.
The procedure for the self-administration by the patient should be reviewed periodically especially if injection site reactions have occurred.
If the patient experiences any break in the skin, which may be associated with swelling or drainage of fluid from the injection site, the patient should be advised to consult with their physician before continuing injections with Rebif. If the patient has multiple lesions, Rebif should be discontinued until healing has occurred. Patients with single lesions may continue provided that the necrosis is not too extensive.
In clinical trials with Rebif, asymptomatic elevations of hepatic transaminases (particularly alanine aminotransferase (ALT)) were common and 1-3% of patients developed elevations of hepatic transaminases above 5 times the upper limit of normal (ULN). In the absence of clinical symptoms, serum ALT levels should be monitored prior to the start of therapy, at months 1, 3 and 6 on therapy and periodically thereafter. Dose reduction of Rebif should be considered if ALT rises above 5 times the ULN, and gradually re-escalated when enzyme levels have normalized. Rebif should be initiated with caution in patients with a history of significant liver disease, clinical evidence of active liver disease, alcohol abuse or increased serum ALT (>2.5 times ULN). Treatment with Rebif should be stopped if icterus or other clinical symptoms of liver dysfunction appear (see section 4.8).
Rebif, like other interferons beta, has a potential for causing severe liver injury (see section 4.8) including acute hepatic failure. The mechanism for the rare symptomatic hepatic dysfunction is not known. No specific risk factors have been identified.
Laboratory abnormalities are associated with the use of interferons. The overall incidence of these is slightly higher with Rebif 44 than Rebif 22 micrograms. Therefore, in addition to those laboratory tests normally required for monitoring patients with multiple sclerosis, liver enzyme monitoring and complete and differential blood cell counts and platelet counts are recommended at regular intervals (1, 3 and 6 months) following introduction of Rebif therapy and then periodically thereafter in the absence of clinical symptoms. These should be more frequent when initiating Rebif 44 micrograms.
Patients being treated with Rebif may occasionally develop new or worsening thyroid abnormalities. Thyroid function testing is recommended at baseline and if abnormal, every 6-12 months following initiation of therapy. If tests are normal at baseline, routine testing is not needed but should be performed if clinical findings of thyroid dysfunction appear (see section 4.8).
Caution should be used, and close monitoring considered when administering interferon beta-1a to patients with severe renal and hepatic failure and to patients with severe myelosuppression.
Serum neutralising antibodies against interferon beta-1a may develop. The precise incidence of antibodies is as yet uncertain. Clinical data suggest that after 24 to 48 months of treatment with Rebif 22 micrograms, approximately 24% of patients develop persistent serum antibodies to interferon beta-1a and after 24 to 48 months of treatment with Rebif 44 micrograms, approximately 13 to 14% of patients develop persistent serum antibodies to interferon beta-1a. The presence of antibodies has been shown to attenuate the pharmacodynamic response to interferon beta-1a (Beta-2 microglobulin and neopterin). Although the clinical significance of the induction of antibodies has not been fully elucidated, the development of neutralising antibodies is associated with reduced efficacy on clinical and MRI variables. If a patient responds poorly to therapy with Rebif, and has neutralising antibodies, the treating physician should reassess the benefit/risk ratio of continued Rebif therapy.
The use of various assays to detect serum antibodies and differing definitions of antibody positivity limits the ability to compare antigenicity among different products.
Only sparse safety and efficacy data are available from non-ambulatory patients with multiple sclerosis. Rebif has not yet been investigated in patients with primary progressive multiple sclerosis and should not be used in such patients.
Rebif 8.8 mcg and Rebif 22 mcg:
This medicinal product contains 1.0 mg benzyl alcohol per dose of 0.2 ml and 2.5 mg benzyl alcohol per dose of 0.5 ml.
Rebif 22 mcg:
Rebif 44 mcg:
This medicinal product contains 2.5 mg benzyl alcohol per dose.
Must not be given to premature babies or neonates. May cause toxic reactions and anaphylactoid reactions in infants and children up to 3 years old.
No interaction studies have been performed with interferon beta-1a in humans.
Interferons have been reported to reduce the activity of hepatic cytochrome P450-dependent enzymes in humans and animals. Caution should be exercised when administering Rebif in combination with medicinal products that have a narrow therapeutic index and are largely dependent on the hepatic cytochrome P450 system for clearance, e.g. antiepileptics and some classes of antidepressants.
The interaction of Rebif with corticosteroids or adrenocorticotropic hormone (ACTH) has not been studied systematically. Clinical studies indicate that multiple sclerosis patients can receive Rebif and corticosteroids or ACTH during relapses.
Women of child-bearing potential
Women of child-bearing potential should take appropriate contraceptive measures. If the patient becomes pregnant or plans to become pregnant while taking Rebif she should be informed of the potential hazards and discontinuation of therapy should be considered (see section 5.3). In patients with a high relapse rate before treatment has started, the risk of a severe relapse following discontinuation of Rebif in the event of pregnancy should be weighed against a possible increased risk of spontaneous abortion.
Pregnancy
There is limited information on the use of Rebif in pregnancy. Available data indicates that there may be an increased risk of spontaneous abortion. Therefore initiation of treatment is contraindicated during pregnancy (see section 4.3).
Breastfeeding
It is not known whether Rebif is excreted in human milk. Because of the potential for serious adverse reactions in breast-fed infants, a decision should be made whether to discontinue breast-feeding or Rebif therapy.
Central nervous system-related adverse events associated with the use of interferon beta (e.g. dizziness) might influence the patient's ability to drive or use machines (see section 4.8).
The highest incidence of adverse reactions associated with Rebif therapy is related to flu-like syndrome. Flu-like symptoms tend to be most prominent at the initiation of therapy and decrease in frequency with continued treatment. Approximately 70% of patients treated with Rebif can expect to experience the typical interferon flu-like syndrome within the first six months after starting treatment. Approximately 30% of patients will also experience reactions at the injection site, predominantly mild inflammation or erythema. Asymptomatic increases in laboratory parameters of hepatic function and decreases in white blood cells (WBC) are also common.
The majority of adverse reactions observed with IFN beta-1a are usually mild and reversible, and respond well to dose reductions. In case of severe or persistent undesirable effects, the dose of Rebif may be temporarily lowered or interrupted, at the discretion of the physician.
The adverse reactions reported below are classified according to frequency of occurrence as follows:
|
|
|
|
|
|
|
|
|
|
|
|
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
The data presented is obtained from pooled clinical studies in multiple sclerosis (placebo=824 patients; Rebif 22 micrograms three times per week (TIW)=398 patients; Rebif 44 micrograms TIW=727 patients) and shows the frequency of adverse reactions observed at six months (excess over placebo). Adverse reactions are listed below by frequency of occurrence and by MedDRA System Organ Class.
|
|
|
|
|
|
|
| ||
|
|
| ||
|
| |||
|
| |||
|
|
| ||
|
|
| ||
|
| |||
|
| |||
|
| |||
|
| |||
|
| |||
|
|
| ||
|
| |||
|
|
|
| |
|
|
|
*Adverse reactions identified during post marketing surveillance (frequency not known)
Interferon beta has a potential for causing severe liver injury. The mechanism for the rare symptomatic hepatic dysfunction is not known. The majority of the cases of severe liver injury occurred within the first six months of treatment. No specific risk factors have been identified. Treatment with Rebif should be stopped if icterus or other clinical symptoms of liver dysfunction appear (see section 4.4).
The administration of interferons has been associated with anorexia, dizziness, anxiety, arrhythmias, vasodilation and palpitation, menorrhagia and metrorrhagia.
An increased formation of auto-antibodies may occur during treatment with interferon beta.
In case of overdose, patients should be hospitalised for observation and appropriate supportive treatment should be given.
Pharmacotherapeutic group: Immunostimulants, Interferons, ATC code: L03AB07.
Interferons (IFNs) are a group of endogenous glycoproteins endowed with immunomodulatory, antiviral and antiproliferative properties.
Rebif (interferon beta-1a) shares the same amino acid sequence with endogenous human interferon beta. It is produced in mammalian cells (Chinese hamster ovary) and is therefore glycosylated like the natural protein.
The precise mechanism of action of Rebif in multiple sclerosis is still under investigation.
The safety and efficacy of Rebif has been evaluated in patients with relapsing-remitting multiple sclerosis at doses ranging from 11 to 44 micrograms (3-12 million IU), administered subcutaneously three times per week. At licensed posology, Rebif 22 micrograms has been demonstrated to decrease the incidence (approximately 30% over 2 years) and severity of clinical relapses in patients with at least 2 exacerbations in the previous 2 years and with an EDSS of 0-5.0 at entry. The proportion of patients with disability progression, as defined by at least one point increase in EDSS confirmed three months later, was reduced from 39% (placebo) to 30% (Rebif 22 micrograms). Over 4 years, the reduction in the mean exacerbation rate was 22% in patients treated with Rebif 22 micrograms, and 29% in patients treated with Rebif 44 micrograms group compared with a group of patients treated with placebo for 2 years and then either Rebif 22 or Rebif 44 micrograms for 2 years.
In a 3-year study in patients with secondary progressive multiple sclerosis (EDSS 3-6.5) with evidence of clinical progression in the preceding two years and who had not experienced relapses in the preceding 8 weeks, Rebif had no significant effect on progression of disability, but relapse rate was reduced by approximately 30%. If the patient population was divided into 2 subgroups (those with and those without relapses in the 2-year period prior to study entry), there was no effect on disability in patients without relapses, but in patients with relapses, the proportion with progression in disability at the end of the study was reduced from 70% (placebo) to 57% (Rebif 22 micrograms and 44 micrograms combined). These results obtained in a subgroup of patients a posteriori should be interpreted cautiously.
Rebif has not yet been investigated in patients with primary progressive multiple sclerosis, and should not be used in such patients.
In healthy volunteers after intravenous administration, interferon beta-1a exhibits a sharp multi-exponential decline, with serum levels proportional to the dose. The initial half-life is in the order of minutes and the terminal half-life is several hours, with the possible presence of a deep compartment. When administered by the subcutaneous or intramuscular routes, serum levels of interferon beta remain low, but are still measurable up to 12 to 24 hours post-dose. Subcutaneous and intramuscular administrations of Rebif produce equivalent exposure to interferon beta. Following a single 60 microgram dose, the maximum peak concentration, as measured by immunoassay, is around 6 to 10 IU/ml, occurring on average around 3 hours after the dose. After subcutaneous administration at the same dose repeated every 48 hours for 4 doses, a moderate accumulation occurs (about 2.5 x for AUC).
Regardless of the route of dosing, pronounced pharmacodynamic changes are associated with the administration of Rebif. After a single dose, intracellular and serum activity of 2-5A synthetase and serum concentrations of beta-2 microglobulin and neopterin increase within 24 hours, and start to decline within 2 days. Intramuscular and subcutaneous administrations produce fully superimposable responses. After repeated subcutaneous administration every 48 hours for 4 doses, these biological responses remain elevated, with no signs of tolerance development.
Interferon beta-1a is mainly metabolised and excreted by the liver and the kidneys.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated-dose toxicity, and genotoxicity.
Rebif has not been investigated for carcinogenicity.
A study on embryo/foetal toxicity in monkeys showed no evidence of reproductive disturbances. Based on observations with other alpha and beta interferons, an increased risk of abortions cannot be excluded. No information is available on the effects of the interferon beta-1a on male fertility.
Mannitol
Poloxamer 188
L-methionine
Benzyl alcohol
Sodium acetate
Acetic acid for pH adjustment
Sodium hydroxide for pH adjustment
Water for injections
Not applicable.
18 months.
Store in a refrigerator (2°C – 8°C) away from the cooling element. Do not freeze. Store in the original package in order to protect from light.
For the purpose of ambulatory use, the patient may remove Rebif from the refrigerator and store it not above 25°C for one single period of up to 14 days. Rebif must then be returned to the refrigerator and used before the expiry date.
Rebif 22 mcg and Rebif 44 mcg:
One ml type 1 glass syringe, with a stainless steel needle, containing 0.5 ml solution.
The syringe is sealed in a disposable pen injector called RebiDose.
Pack sizes of 1, 3 or 12 pre-filled pens.
Not all pack sizes may be marketed.
Rebif 8.8. mcg and Rebif 22 mcg:
For patients initiating treatment with Rebif, Rebif 8.8 micrograms and Rebif 22 micrograms are available in an initiation pack composed of 6 individual doses of a 1 ml type 1 glass syringe with a stainless steel needle containing 0.2 ml of Rebif 8.8 micrograms solution for injection and 6 individual doses of a 1 ml type 1 glass syringe with a stainless steel needle containing 0.5 ml of Rebif 22 micrograms for solution for injection. The syringes are sealed in disposable pen injectors called RebiDose.
The solution for injection in a pre-filled pen is ready for use. The carton contains a package leaflet with full instructions for use and handling.
For single use only. Only clear to opalescent solution without particles and without visible signs of deterioration should be used.
Any unused product or waste material should be disposed of in accordance with local requirements.
Merck Serono Europe Limited
56, Marsh Wall
London E14 9TP
United Kingdom
Rebif 22 mcg:
EU/1/98/063/011
EU/1/98/063/012
EU/1/98/063/013
Rebif 44 mcg:
EU/1/98/063/014
EU/1/98/063/014
EU/1/98/063/016
Rebif 8.8. mcg and Rebif 22 mcg:
EU/1/98/063/017
Date of first authorisation: 4th May 1998
Date of latest renewal: 4th May 2008
08/2011
Detailed information on this product is available on the website of the European Medicines Agency
http://www.ema.europa.eu
Ropinirol dura may be available in the countries listed below.
Ropinirole hydrochloride (a derivative of Ropinirole) is reported as an ingredient of Ropinirol dura in the following countries:
International Drug Name Search
Cefex may be available in the countries listed below.
Cefalexin is reported as an ingredient of Cefex in the following countries:
International Drug Name Search
Indomen may be available in the countries listed below.
Indometacin is reported as an ingredient of Indomen in the following countries:
International Drug Name Search
Primolut-Depot may be available in the countries listed below.
Hydroxyprogesterone caproate (a derivative of Hydroxyprogesterone) is reported as an ingredient of Primolut-Depot in the following countries:
International Drug Name Search
Broncho-Pectoralis Codeine may be available in the countries listed below.
Codeine is reported as an ingredient of Broncho-Pectoralis Codeine in the following countries:
International Drug Name Search
Myoxam may be available in the countries listed below.
Midecamycin diacetate (a derivative of Midecamycin) is reported as an ingredient of Myoxam in the following countries:
International Drug Name Search
Cortixyl Depot may be available in the countries listed below.
Betamethadol is reported as an ingredient of Cortixyl Depot in the following countries:
Betamethasone is reported as an ingredient of Cortixyl Depot in the following countries:
International Drug Name Search
Furosemid acis may be available in the countries listed below.
Furosemide is reported as an ingredient of Furosemid acis in the following countries:
International Drug Name Search
Ceftriaxone Labesfal may be available in the countries listed below.
Ceftriaxone is reported as an ingredient of Ceftriaxone Labesfal in the following countries:
International Drug Name Search
Calcium Heumann may be available in the countries listed below.
Calcium Carbonate is reported as an ingredient of Calcium Heumann in the following countries:
International Drug Name Search
In the US, Cefprozil (cefprozil systemic) is a member of the drug class second generation cephalosporins and is used to treat Bladder Infection, Bronchitis, Kidney Infections, Otitis Media, Pneumonia, Sinusitis, Skin Infection, Tonsillitis/Pharyngitis and Upper Respiratory Tract Infection.
US matches:
Rec.INN
J01DC10
0092665-29-7
C18-H19-N3-O5-S
389
Antibacterial: Cephalosporin
(6R,7R)-7-[(R)-2-amino-2-(p-hydroxyphenyl)acetamido]-8-oxo-3-propenyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
International Drug Name Search
Glossary
| BAN | British Approved Name |
| DCF | Dénomination Commune Française |
| IS | Inofficial Synonym |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
Rec.INN
R03AC
0034391-04-3
C13-H21-N-O3
239
Antiasthmatic agent
Ăź₂-Sympathomimetic agent
(1R)-2-[(1,1-Dimethylethyl)amino)-1-[4-hydroxy-3-(hydroxymethyl)phenyl]ethanol
(R)-alpha-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-1,3-benzenedimethanol
(R)-alpha-[(tert-Butylamino)methyl]-4-hydroxy-3-(hydroxymethyl)benzylalkohol (IUPAC)
(R)-alpha-[tert-butylamino)methyl]-4-hydroxy-m-xylene-alpha,alpha'-diol (WHO)
International Drug Name Search
Glossary
| IUPAC | International Union of Pure and Applied Chemistry |
| IS | Inofficial Synonym |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
| WHO | World Health Organization |
Beta-Histina Generis may be available in the countries listed below.
Betahistine dihydrochloride (a derivative of Betahistine) is reported as an ingredient of Beta-Histina Generis in the following countries:
International Drug Name Search
Cefuroxim Aristo may be available in the countries listed below.
Cefuroxime sodium salt (a derivative of Cefuroxime) is reported as an ingredient of Cefuroxim Aristo in the following countries:
International Drug Name Search
Cadens may be available in the countries listed below.
Calcitonin is reported as an ingredient of Cadens in the following countries:
International Drug Name Search
Laktipex may be available in the countries listed below.
Lactulose is reported as an ingredient of Laktipex in the following countries:
International Drug Name Search
Lisinopril PSI may be available in the countries listed below.
Lisinopril dihydrate (a derivative of Lisinopril) is reported as an ingredient of Lisinopril PSI in the following countries:
International Drug Name Search
Meloxistad may be available in the countries listed below.
Meloxicam is reported as an ingredient of Meloxistad in the following countries:
International Drug Name Search
Ifosfamida Filaxis may be available in the countries listed below.
Ifosfamide is reported as an ingredient of Ifosfamida Filaxis in the following countries:
International Drug Name Search
Gatiflox may be available in the countries listed below.
Gatifloxacin is reported as an ingredient of Gatiflox in the following countries:
International Drug Name Search
Azaprin may be available in the countries listed below.
Azathioprine is reported as an ingredient of Azaprin in the following countries:
International Drug Name Search
Lisinopril-HCT G.L. may be available in the countries listed below.
Hydrochlorothiazide is reported as an ingredient of Lisinopril-HCT G.L. in the following countries:
Lisinopril dihydrate (a derivative of Lisinopril) is reported as an ingredient of Lisinopril-HCT G.L. in the following countries:
International Drug Name Search
Ciprodac may be available in the countries listed below.
Ciprofloxacin is reported as an ingredient of Ciprodac in the following countries:
International Drug Name Search
Ketolef may be available in the countries listed below.
Ketoconazole is reported as an ingredient of Ketolef in the following countries:
International Drug Name Search
Isopto-Karbakolin may be available in the countries listed below.
Carbachol is reported as an ingredient of Isopto-Karbakolin in the following countries:
International Drug Name Search
CĂ©liprolol Actavis may be available in the countries listed below.
Celiprolol hydrochloride (a derivative of Celiprolol) is reported as an ingredient of CĂ©liprolol Actavis in the following countries:
International Drug Name Search
Fluminex may be available in the countries listed below.
Flunisolide is reported as an ingredient of Fluminex in the following countries:
International Drug Name Search
Apocillin may be available in the countries listed below.
Phenoxymethylpenicillin potassium (a derivative of Phenoxymethylpenicillin) is reported as an ingredient of Apocillin in the following countries:
International Drug Name Search
Macrodex 60 mg/ml med natriumklorid may be available in the countries listed below.
Dextran average molecular weight about 70000 (a derivative of Dextran) is reported as an ingredient of Macrodex 60 mg/ml med natriumklorid in the following countries:
International Drug Name Search
Capabiotic may be available in the countries listed below.
Cefaclor is reported as an ingredient of Capabiotic in the following countries:
International Drug Name Search
Beclometason may be available in the countries listed below.
Beclometasone 17α,21-dipropionate (a derivative of Beclometasone) is reported as an ingredient of Beclometason in the following countries:
International Drug Name Search
Aluminum Chlorohydrate may be available in the countries listed below.
Aluminum Chlorohydrate (USAN) is also known as Aluminium Chlorohydrate
International Drug Name Search
Glossary
| USAN | United States Adopted Name |
In some countries, this medicine may only be approved for veterinary use.
Chloramphenicol is reported as an ingredient of Anacetin in the following countries:
International Drug Name Search
Glicron may be available in the countries listed below.
Gliclazide is reported as an ingredient of Glicron in the following countries:
International Drug Name Search
Feniallerg may be available in the countries listed below.
Dimetindene maleate (a derivative of Dimetindene) is reported as an ingredient of Feniallerg in the following countries:
International Drug Name Search
Azaprine may be available in the countries listed below.
Azathioprine is reported as an ingredient of Azaprine in the following countries:
International Drug Name Search
Ferimax IM may be available in the countries listed below.
Iron Polymaltose is reported as an ingredient of Ferimax IM in the following countries:
International Drug Name Search
Edical may be available in the countries listed below.
Calcium Carbonate is reported as an ingredient of Edical in the following countries:
International Drug Name Search
Co-Trimoxazol-Akri may be available in the countries listed below.
Sulfamethoxazole is reported as an ingredient of Co-Trimoxazol-Akri in the following countries:
Trimethoprim is reported as an ingredient of Co-Trimoxazol-Akri in the following countries:
International Drug Name Search
Clofend may be available in the countries listed below.
Cloperastine fendizoate (a derivative of Cloperastine) is reported as an ingredient of Clofend in the following countries:
International Drug Name Search
Rapidocain may be available in the countries listed below.
Lidocaine hydrochloride (a derivative of Lidocaine) is reported as an ingredient of Rapidocain in the following countries:
International Drug Name Search
Mucofor may be available in the countries listed below.
Erdosteine is reported as an ingredient of Mucofor in the following countries:
International Drug Name Search
Aciflox may be available in the countries listed below.
Sparfloxacin is reported as an ingredient of Aciflox in the following countries:
International Drug Name Search
Beta-Histina Ciclum may be available in the countries listed below.
Betahistine is reported as an ingredient of Beta-Histina Ciclum in the following countries:
International Drug Name Search
Rec.INN
0000092-31-9
C15-H16-Cl-N3-S
305
Hemostatic agent
Antidote in methemoglobinemia
Phenothiazin-5-ium, 3-amino-7-(dimethylamino)-2-methyl-, chloride
International Drug Name Search
Glossary
| IS | Inofficial Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Baydol may be available in the countries listed below.
Acemetacin is reported as an ingredient of Baydol in the following countries:
International Drug Name Search
Gliclazide RPG may be available in the countries listed below.
Gliclazide is reported as an ingredient of Gliclazide RPG in the following countries:
International Drug Name Search
Pentozed may be available in the countries listed below.
Domperidone is reported as an ingredient of Pentozed in the following countries:
Pantoprazole is reported as an ingredient of Pentozed in the following countries:
International Drug Name Search
Cortiespec may be available in the countries listed below.
Fluocinolone Acetonide is reported as an ingredient of Cortiespec in the following countries:
International Drug Name Search
Trochain may be available in the countries listed below.
Benzocaine is reported as an ingredient of Trochain in the following countries:
Cetrimide is reported as an ingredient of Trochain in the following countries:
International Drug Name Search
Belderil may be available in the countries listed below.
Voglibose is reported as an ingredient of Belderil in the following countries:
International Drug Name Search
Minifor may be available in the countries listed below.
Metformin hydrochloride (a derivative of Metformin) is reported as an ingredient of Minifor in the following countries:
International Drug Name Search
Folcasin may be available in the countries listed below.
Calcium Folinate is reported as an ingredient of Folcasin in the following countries:
International Drug Name Search
Merck-Pethidine HCl may be available in the countries listed below.
Pethidine hydrochloride (a derivative of Pethidine) is reported as an ingredient of Merck-Pethidine HCl in the following countries:
International Drug Name Search
Co-Epril may be available in the countries listed below.
Enalapril maleate (a derivative of Enalapril) is reported as an ingredient of Co-Epril in the following countries:
Hydrochlorothiazide is reported as an ingredient of Co-Epril in the following countries:
International Drug Name Search
Acemet may be available in the countries listed below.
Acemetacin is reported as an ingredient of Acemet in the following countries:
International Drug Name Search
Anadvil Rhume may be available in the countries listed below.
Ibuprofen is reported as an ingredient of Anadvil Rhume in the following countries:
Pseudoephedrine hydrochloride (a derivative of Pseudoephedrine) is reported as an ingredient of Anadvil Rhume in the following countries:
International Drug Name Search
